Videos
  • Featured
  • Topics
  • Partners
  • Register
  • Login
Filters 254 Videos
Upload Date
  • Today
  • This Week
  • This Month
  • This Year
Category
  • Innovations
  • Research
  • Sites & Resources
  • Services
  • Thought Leaders
  • Events & Education
  • Advocacy
Fireside Chat – Bill Burkoth – Pfizer Ventures

White Hat

10/18/2018
Fireside Chat – Bill Burkoth – Pfizer Ventures

Bill Burkoth is currently an Executive Director of Pfizer Ventures, the venture capital arm of Pfizer Inc. Since joining Pfizer in early 2004, Bill has played an instrumental role in numerous new venture capital investments, including Avid Radiopharmaceuticals (acquired by Eli Lilly), Clovis Oncology (Nasdaq: CLVS), DVS Sciences (acquired by Fluidigm), Evolution Benefits (acquired by Genstar Capital), HandyLab (acquired by Becton Dickinson), and HD Biosciences (acquired by Wuxi AppTec).  Bill currently serves on the board of directors of AMRA, Biodesy, DIR Technologies, G-Con Manufacturing, NeuMoDx Molecular, Novocure (Nasdaq: NVCR), Palleon Pharma, RefleXion Medical, and Strata Oncology.  He is also a member of the investment committee of the Investment Fund for Health in Africa (IFHA) and FinHealth Gestão de Recursos S.A. (Rio, Brazil).  Prior to joining Pfizer, Bill worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his roles in business development, Bill was an analyst at Bay City Capital. Mr. Burkoth received a BA in chemistry from Whitman College and an MBA from Columbia Business School.




Patient Driven Innovation and Investing

White Hat

10/18/2018
Patient Driven Innovation and Investing

Tammy Crawford is the Founder and Executive Director of Focus on Lyme and leads the team in achieving its mission to improve diagnostics, treatment, prevention, and advocacy for patients suffering from Lyme and associated tick-borne disease.  Tammy was inspired to create Focus on Lyme by her daughter Jessica’s journey and is motivated every day to try to ensure no one has to experience what she did.




Calimmune - A case study from the innovator and investor perspective

White Hat

10/18/2018
Calimmune - A case study from the innovator and investor perspective

Calimmune, Inc. (acquired by CSL Limited in 2017) is the 2018 Arizona Bioscience Company of the Year.   

Louis Breton is the former CEO of Calimmune, Inc., a gene therapy development company he co-founded with Nobel Laureate Dr. David Baltimore, which was recently acquired by CSL Behring.  Calimmune focused on liberating patients from chronic and currently incurable diseases.  Mr. Breton is a husband, father, Chaplain, inventor, author, mentor, serial entrepreneur and is involved in local charities.  He has a career in biotechnology spanning more than 2 decades.  He has now built and successfully sold 3 life science focused companies, including a biotech consulting firm.  He has raised more than $100M for the companies he has launched, and has conducted approximately 500 licensing deals with academic and government institutions.  He has established international subsidiaries, negotiated with global regulatory bodies, and has collaborated with ministries of health of multiple governments.  He has been intimately involved in more than 20 different product launches.  He has been a board member of 12 biotech and high tech companies, and was a Business Advisory Council member for a sitting president.  Mr. Breton has presented to the House of Lords, and participated in a special conference at the Vatican to bridge faith and science.  In the last decade, he has helped to craft a new paradigm for the delivery of stem cell gene therapy and regenerative medicine, and is now taking on the esteemed roles of chauffer, Dance Dad, swim instructor, baby sitter and courier.  

Harry George, President and CFO, Radiance Therapeutics, Inc.  

For over four decades, Harry George has been starting, funding, and operating rapid-growth technology companies.  In 1995, Harry co-founded Solstice Capital, an early-stage venture capital firm with offices in Boston and Tucson, which raised $80M in two funds.  Solstice was active until 2015 and invested in 44 companies that generated positive returns for both funds.   In 1981, prior to Solstice, Harry was the co-founder, a director and the CFO of Interleaf, Inc., a pioneer in electronic publishing.  Interleaf was the seventh-fastest growing private company in the US for a five-year period and went public in 1986 with 800 employees. In January of 2000, Interleaf was acquired by BroadVision for $900M. Before Interleaf, in 1973, Harry was a co-founder, a director and the CFO of Kurzweil Computer Products, the leader in optical character recognition and early use of AI.   Mr. George has served on 26 boards for both public and private companies.  He is currently serving on the boards of HTGMolecular, Medipacs, PostBidShip, RxActuator, Medipacs, Radiance and Splash Pharmaceuticals. Mr. George has been active in a number of community organizations and has served as Treasurer of both the Arizona-Sonora Desert Museum and the Tucson Museum of Art. He is currently a board member of the Southern Arizona Leadership Council and, earlier, helped start Tucson’s Desert Angels and Start-up Tucson.  Mr. George graduated from Bowdoin College and was given an Honorary Doctor of Science from the U of A in 2012.  

Moderator:  John M. (Jock) Holliman, III, Valley Ventures;  Executive Chairman at LipimetiX Development and Capstone Therapeutics.  Since February 1993, Jock has been a general partner of entities, which are the general partners of Valley Ventures, LP (formerly known as Arizona Growth Partners, LP), Valley Ventures II, LP, Valley Ventures III Annex, LP, all of which are venture capital funds that invest principally in life science companies.  He also serves in an executive capacity at Capstone Therapeutics, Inc. He became Executive Chairman and Principal Executive Officer of Capstone on April 5, 2006 and has served as a director of the company since September 1987 and as Chairman of the Board of Directors since August 1997.




AZBio Multiple Interviews

AZBio Members

05/17/2013
AZBio Multiple Interviews

  • << First
  • < Previous
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • Next >
  • Last >>

Privacy Statement

ON-LINE PRIVACY PRACTICES

Privacy Statement..

Legal Notes

ON-LINE LEGAL PRACTICES

Legal Notes…

Links

  • What is AZBio.tv?
  • Customer Support
  • Become an Advertiser

Media Contact

480-779-8101

AdvancingBio@AZbio.org

Follow Us On

  • Home
  • Privacy
  • Legal Notes

© Copyright 2021 Arizona BioIndustry Association | 480-779-8101

Powered By New Angle Media